Table 1.

Immune response elicited by PTM-modified TAA.

PTMs	TAA	Type of Tumor in Which TAA Has Been Identified or to Which the Antigen Is Associated	Immune Recognition (If Any)	References
Acetylation	ENO1	Pancreas	NA	[16]
	p53	Colon, Prostrate, Pharynx	CD4+ T Cell	[19]
Phosphorylation	MART-1	Melanoma, Leukemia	CD4+ T Cell	[29]
	IRS2	Melanoma, Breast, Ovary, Colon	CD8+ T Cell	[18,30,31]
	β-Catenin	Ovary, Melanoma	CD8+ T Cell	[30,31]
	Breast cancer antiestrogen resistance 3	Melanoma	CD8+ T Cell	[30]
	p53	Head and Neck	CD4+ T Cell	[21]
	ENO1	Pancreas	Ab, CD4+ T Cell	[14,15]
	CDC25b	Melanoma, Breast, Ovary, Colon, Leukemia	CD8+ T Cell	[18,31]
	TNF receptor associated protein (TRAP-1)	Lung	CD8+ T Cell	[32]
	Vim	Colon	CD4+ T cells	[33]
Citrullination	Vim	Melanoma, Lung	CD4+ T Cell	[17,34,35,36]
	Enolase	Melanoma, Lung	CD4+ T Cell	[17,35,36,37]
Glycosylation	MUC1	Breast, Ovary	CD8+ T Cell, Ab	[38,39]
Sialylation	Silayl-Tn-Antigen	Breast, Ovary	Ab (IgM)	[40,41,42,43]
SUMOylation	p53	Sarcoma	NA	[44]
Methylation	Enolase	Pancreas	NA	[16]